ASPIRE (Asia Pacific Policy Review and Engagement) for Lung Cancer is a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms. We advocate for prioritizing lung cancer in government action plans, aiming to drive transformative changes that enhance patient access and care.
Our focus is guided by a Charter outlining nine key pillars, with an initial emphasis on political action and funding, in turn leading to improved equitable access to screening, diagnosis and treatment and overall patient care.
We believe in the influence of collaboration and collective action to drive positive change. Therefore, we will work with governments, agencies, NGOs and patient groups, bringing together multi-disciplinary experts to improve health outcomes for lung cancer patients in the APAC region.
To address Asia-Pacific lung cancer challenges, there is a need for a unified voice to mobilize resources and spur governments and policymakers into action. We set out four key aims:
Lung cancer is the most diagnosed cancer and the leading cause of cancer deaths in the Asia-Pacific region
projected by 2040 due to lung cancer. Current annual death rate is estimated at around 1 million
contributed by lung cancer as it is ranked as the most prevalent cancer
amounted as the annual global cost due to lung cancer, imposing the highest economic burden on health systems
ASPIRE's initiatives are made possible through the support of AstraZeneca, Amgen, Johnson & Johnson, Pfizer, Roche Diagnostics, and Siemens Healthineers. The secretariat is managed by EquiHealth, bridging between non-profits, policymakers and the private sector.
If you would like to learn more about us or join our efforts to improve lung cancer outcomes in the Asia Pacific region, please contact us.
We are a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms.
